Allogene Therapeutics ALLO 深 滬
等待開盤 07-18 09:30:00 美东时间
1.24
+0.010
+0.81%
華盛通- 最 高1.27
- 今 開1.24
- 成交量 177.27万股
- 最 低 1.23
- 昨 收 1.23
- 總市值 2.72亿
- 52周最高 3.78
- 市盈率 靜 --
- 換手率 0.81%
- 52周最低 0.8621
- 委 比 -46.80%
- 總股本 2.19亿
- 歷史最高 55.00
- 量 比 0.53
- 振 幅 3.25%
- 歷史最低 0.8621
- 每 手 1
- 風險率 0.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多暴涨730%！iNKT疗法用一个临床案例点燃实体瘤革命，中国追赶在即
（来源：求实药社） 2.6亿市值跃升：一个临床案例如何撼动华尔街？ 2025年7月11日，MiNK Therapeutics（NASDAQ: INKT）宣布其异...
07-16 12:01
Play Selects Allot DNS Secure to Offer Cyber Protection to Its Broadband Customers
Allot Ltd has expanded its cybersecurity partnership with Play, a leading Polish convergent operator, by providing DNS Secure services to fixed broadband customers. This agreement, signed in April 2025, builds on the existing NetworkSecure deployment for Play's mobile customers. DNS Secure offers protection against cyber threats like malware and phishing, and can be integrated with other Allot solutions. Play is satisfied with Allot's services, a...
07-16 09:58
Pierre Fabre Pharma Announces Transfer Of IND Application For Tabelecleucel From Its Partner, Atara Biotherapeutics
Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical programEnrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) investigating
07-15 20:19
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
Allarity Therapeutics has dosed the second patient in its new Phase 2 trial evaluating stenoparib for advanced ovarian cancer patients, particularly those with platinum-resistant or platinum-ineligible disease. Stenoparib, a dual PARP and WNT pathway inhibitor, has shown durable clinical benefit and tolerability in earlier studies. The trial also aims to advance Allarity’s DRP® companion diagnostic to identify patients most likely to benefit from...
06-27 12:00
新浪财经ESG：ALLO MSCI（明晟）ESG评级调升至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
06-27 07:00
Allot Announces Pricing of Underwritten Public Offering of Ordinary Shares
Allot Ltd. announced the pricing of a public offering of 5,000,000 ordinary shares at $8.00 per share, with an additional option for underwriters to purchase up to 750,000 shares. Gross proceeds are expected to be $40 million, to be used for repaying $31.41 million in debt and general corporate purposes. The offering is expected to close on June 26, 2025.
06-25 00:28
Sana Biotechnology Announces 6-Month Follow-Up Results From First-In-Human Study Transplanting UP421, Allogeneic Primary Islet Cell Therapy Engineered With Sana's HIP Technology, Into Patient With T1D Without Any Immunosuppression
Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without ImmunosuppressionSix-Month Patient Follow-up Results Demonstrate that Sana's
06-23 22:07
Nelnet Gains $175M from ALLO Holdings Redemption
The latest announcement is out from Nelnet ( ($NNI) ). On June 4, 2025, Nelnet,...
06-05 04:28
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Allogene Therapeutics reported promising Phase 1b data for ALLO-316, an allogeneic CAR T therapy targeting CD70 in advanced renal cell carcinoma (RCC). In a cohort of 16 patients with CD70 TPS ≥50%, ALLO-316 achieved a 31% confirmed overall response rate, with four of five responders maintaining ongoing responses, including one over 12 months. The therapy demonstrated robust expansion and tumor infiltration, supported by the Dagger® technology. S...
06-01 14:45
SA Asks: Which oncology companies are attractive M&A targets?
Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology (NASDA...
05-31 03:00
